10-Q: Ocular Therapeutix Reports Q2 Loss Amid R&D Surge

Ocular Therapeutix, Inc. reported increased net losses and decreased product revenue in Q2 2025, driven by significant R&D investments in its late-stage retinal disease programs, while extending its cash runway into 2028.

Summary

• Net loss for the three months ended June 30, 2025, increased to $67.8 million from $43.8 million in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $131.9 million from $108.6 million in the prior year period.
• Product revenue, primarily from DEXTENZA, decreased by 18.3% to $13.4 million for Q2 2025 and by 22.8% to $24.0 million for the six months ended June 30, 2025, compared to the same periods in 2024.
• Research and development expenses significantly increased by $22.2 million to $51.1 million in Q2 2025 and by $44.3 million to $93.9 million for the six months ended June 30, 2025, primarily due to the progression of AXPAXLI Phase 3 trials (SOL-1 and SOL-R).
• Selling and marketing expenses increased by $3.7 million to $13.7 million in Q2 2025 and by $7.7 million to $27.9 million for the six months ended June 30, 2025, driven by corporate branding and AXPAXLI marketing team expansion.
• General and administrative expenses decreased by $5.4 million to $14.3 million in Q2 2025 and by $3.1 million to $30.7 million for the six months ended June 30, 2025, primarily due to a strategic reduction in force in Q2 2024.
• Cash and cash equivalents stood at $391.1 million as of June 30, 2025, with management projecting this to fund operations into 2028.
• In-Market Sales (demand) for DEXTENZA increased to approximately 44,000 units in Q2 2025, up from 42,000 units in Q2 2024 and 40,000 units in Q1 2025.
• Gross-to-Net (GTN) provisions for DEXTENZA increased to 51.7% of gross sales in Q2 2025, up from 39.6% in Q2 2024, due to pricing strategy adjustments including increased Off-Invoice Discounts (OID).

Sentiment

Score: 6

Explanation: While current financial results show increased losses and decreased revenue, the significant progress in pivotal clinical trials for AXPAXLI and the extended cash runway into 2028 are strong positive indicators for future potential. The DEXTENZA revenue decline is acknowledged and being addressed with strategic adjustments.

Positives

• AXPAXLI's SOL-1 Phase 3 trial completed randomization of 344 subjects in December 2024, with topline results expected in Q1 2026.
• The FDA agreed to an amendment to the SOL-1 Special Protocol Assessment (SPA) in February 2025, allowing for repeat dosing at Week 52 and Week 76 to support repeat dosing claims.
• AXPAXLI's SOL-R Phase 3 trial completed enrollment, with topline results expected in the first half of 2027.
• The FDA provided positive written feedback on the design of a potential registrational clinical trial for AXPAXLI for non-proliferative diabetic retinopathy (NPDR) in the first half of 2025.
• DEXTENZA received supplemental NDA approval on April 7, 2025, for use in pediatric patients for ocular inflammation and pain following ophthalmic surgery, and for ocular itching associated with allergic conjunctivitis.
• Existing cash and cash equivalents of $391.1 million are expected to fund planned operating expenses, debt service, and capital expenditures into 2028.
• In-Market Sales (demand) for DEXTENZA showed unit growth, indicating clinicians are adjusting to MIPS impact and commercial efforts are effective.

Negatives

• Net loss significantly increased year-over-year, reaching $131.9 million for the six months ended June 30, 2025.
• Product revenue from DEXTENZA decreased by 22.8% for the six months ended June 30, 2025, compared to the prior year, primarily due to pricing strategy, distributor stocking, and buying patterns.
• The inclusion of DEXTENZA into the cost performance category of the Centers for Medicare & Medicaid Services Merit-based Incentive Payment System (MIPS) for 2025 has negatively impacted demand.
• Gross-to-Net (GTN) provisions for DEXTENZA increased substantially, reducing net product revenue.
• Research and development expenses are increasing significantly as clinical trials progress, contributing to higher operating losses.
• Selling and marketing expenses are also increasing, further contributing to operating losses.

Risks

• The company has incurred significant operating losses and negative cash flows since inception and expects this to continue.
• Future viability is dependent on generating cash flows from product sales (DEXTENZA and potential AXPAXLI) and raising additional capital.
• There is no assurance of obtaining additional financing on acceptable terms, which could force delays or reductions in R&D programs or commercialization efforts.
• The amount and timing of future expenses are uncertain and depend on clinical trial progress, regulatory reviews, and commercialization efforts.
• The Barings Credit Facility covenants and collateral pledge may limit the ability to obtain additional debt or other financing.
• The fair value of the derivative liability related to the Barings Credit Agreement is subject to change and cannot be predicted.
• The company is dependent on a small number of third-party manufacturers, posing supply chain risks.
• The industry is subject to rapidly changing technology and substantial competition from pharmaceutical and biotechnology companies.

Future Outlook

The company plans to submit a New Drug Application (NDA) for AXPAXLI for wet AMD if SOL-1 and SOL-R trials yield favorable results, leveraging the 505(b)(2) pathway for potentially faster review. It aims for AXPAXLI to be the first wet AMD product with a superiority label and redosing as infrequently as every 12 months. Further details on a long-term extension study for AXPAXLI for wet AMD and the clinical strategy for AXPAXLI for NPDR and DME are expected in Q3 2025. The company is evaluating next steps for OTX-TIC for OAG or OHT after completing a pilot repeat-dose sub-study. Research and development, selling and marketing, and general and administrative expenses are all anticipated to increase for the remainder of 2025 and beyond as clinical programs advance and commercialization efforts for AXPAXLI intensify.

Management Comments

• We believe the inclusion of re-dosing in the design of the SOL-1 trial enhances the potential of the trial to support a 6-12 month dosing label for AXPAXLI for the treatment of wet AMD and should also provide insights into the long-term durability of AXPAXLI.
• Engagement by subjects and investigator adherence to the rescue protocol of the SOL-1 trial continues to be outstanding.
• The change in SOL-R rescue criteria aligns the trial more closely with how physicians determine when to intervene in the real world in the most conservative manner. This change was not an FDA requirement, but rather a strategic decision to further bridge the gap between clinical trial design and clinical practice.
• We believe that clinicians are starting to adjust to the impact of MIPS, and together with the effects of strong execution by our commercial team and our increased sales efforts directed towards HOPDs, which receive separate payment for DEXTENZA in 2025 after being ineligible for separate payments in 2024, we expect that demand for DEXTENZA continues to grow, as evidenced by sustained unit growth.
• We do not expect to generate significant revenue from the use of DEXTENZA in pediatric patients.
• At this time, we do not anticipate the tariffs and changes in trade policies in place as of the filing of this Quarterly Report on Form 10-Q will have a significant adverse effect on our business or operations.
• Following recent changes more broadly within the FDA, we have not noticed any disruption in the cadence and nature of our dialogue with the FDA to date.
• At this time, we do not anticipate the changes implemented by the OBBB to have a significant adverse effect on our business or operations.

Industry Context

The company operates in the highly competitive and rapidly evolving biotechnology industry, specifically focusing on ophthalmic therapies. Its lead investigational product, AXPAXLI, targets wet age-related macular degeneration (wet AMD), a significant market with existing anti-VEGF therapies. The company's strategy to pursue a superiority label and less frequent dosing for AXPAXLI aims to differentiate it in this crowded space. The commercial product DEXTENZA faces challenges from changes in reimbursement policies like MIPS, which impacts demand, but the company is adapting by focusing on different payment channels (HOPDs) and expects demand growth. The continued investment in R&D for pipeline assets like AXPAXLI and OTX-TIC reflects the industry's high capital requirements and long development cycles for novel therapies.

Comparison to Industry Standards

• The SOL-R trial's modified rescue criteria (loss of >5 ETDRS letters in BCVA plus CSFT increase of 75-microns or more) aligns with real-world clinical decision-making, potentially making the trial results more relevant to physician practice compared to trials with less conservative intervention criteria.
• The company's strategy to seek a superiority label for AXPAXLI based on the SOL-1 trial, with potential redosing as infrequently as every 12 months, aims to differentiate it from current standard-of-care anti-VEGF therapies like aflibercept (Eylea) and bevacizumab (Avastin), which typically require more frequent injections (e.g., Eylea every 8 weeks, Eylea HD every 8, 12, or 16 weeks).
• The use of the 505(b)(2) NDA review pathway for AXPAXLI, leveraging axitinib's existing FDA approval for non-ophthalmic indications, could potentially shorten the review timeline by two months compared to traditional new molecular entity pathways, offering a competitive advantage in market entry speed.
• The negative impact on DEXTENZA demand due to MIPS inclusion highlights the ongoing challenge for pharmaceutical companies to navigate evolving reimbursement landscapes and adapt commercial strategies, a common hurdle in the U.S. healthcare market.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently a party to any material legal proceedings, nor are any material legal proceedings threatened against it.

Related Party Transactions

• The company engaged Boston Image Reading Center LLC (BIRC), where Nadia Waheed (CMO) is a Director, incurring fees of $4,000 for Q2 2025 and $25,000 for YTD Q2 2025.
• The company engaged i2Vision, Inc., affiliated with Jeffrey Heier (CSO) and Peter Kaiser (CDO), incurring fees of $43,000 for Q2 2025 and a net credit of $(121,000) for YTD Q2 2025.
• Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale) ceased to be a related party after Christopher White (former CBO) departed on March 6, 2024. Fees incurred while a related party for YTD Q2 2024 were $1,080,000.
• Heier Consulting, LLC, affiliated with Dr. Heier, provided consulting services until February 21, 2024, when Dr. Heier became CSO. Cash-based fees incurred for YTD Q2 2024 were $5,000.

Stakeholder Impact

• Shareholders: Experience increased net losses and diluted earnings per share, but benefit from extended cash runway and progress in high-potential clinical trials (AXPAXLI). Equity offerings lead to dilution.
• Employees: Benefit from continued employment, stock-based compensation plans (2021 Plan, ESPP), and new employment agreements for key executives. Strategic restructuring in 2024 involved a reduction in force.
• Customers (ASCs, HOPDs, physicians offices): Impacted by DEXTENZA pricing strategy and MIPS inclusion, but company is increasing sales efforts towards HOPDs for better access.
• Suppliers/Manufacturers: Company is dependent on a small number of third-party manufacturers, indicating continued business for these partners.
• Creditors (Barings Finance LLC): Company has significant debt obligations under the Barings Credit Facility, with interest payments and royalty fees tied to DEXTENZA net sales.

Next Steps

• Topline results for the SOL-1 trial are expected in the first quarter of 2026.
• Topline results for the SOL-R trial are expected in the first half of 2027.
• The company plans to provide further details regarding a long-term extension study for AXPAXLI for wet AMD in the third quarter of 2025.
• The company expects to provide further details surrounding its clinical strategy for AXPAXLI for the treatment of NPDR and DME in the third quarter of 2025.
• The company plans to evaluate whether an end-of-Phase 2 meeting with the FDA is appropriate for determining next steps for OTX-TIC for OAG or OHT after completing the pilot repeat-dose sub-study.
• The company anticipates that research and development, selling and marketing, and general and administrative expenses will increase for the remainder of 2025 and beyond.

Key Dates

Recommendation

While the company reported increased net losses and decreased product revenue, which are negative in the short term, these are largely attributable to significant and necessary investments in its late-stage clinical pipeline, particularly AXPAXLI for wet AMD. The progress in the SOL-1 and SOL-R Phase 3 trials, including completed randomization and enrollment, and positive FDA feedback, represents substantial de-risking and potential for future value creation. The extended cash runway into 2028 provides financial stability for these critical development programs. The DEXTENZA revenue decline is a concern, but the company is actively addressing it. Given the high-risk, high-reward nature of biotech, especially with pivotal trial results pending, a 'hold' recommendation is appropriate for investors to await further clinical data and commercialization clarity.

Keywords

Ocular Therapeutix, AXPAXLI, DEXTENZA, Wet AMD, Glaucoma, Ocular Hypertension, Retinal Disease, Biopharmaceutical, Clinical Trials, Phase 3, FDA Approval, SEC Filing, Biotech, Ophthalmology, ELUTYX